TGFβ controls ovarian cancer cell proliferation

There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research...

Descripción completa

Detalles Bibliográficos
Autores: Alsina Sanchís, Elisenda, Figueras i Amat, Agnès, Lahiguera, Álvaro, Gil-Martín, Marta, Pardo, Beatriz, Piulats, Josep M., Martí, Lola, Ponce i Sebastià, Jordi, Matias-Guiu, Xavier, 1958-, Vidal-Bel, August, Villanueva Garatachea, Alberto, Viñals Canals, Francesc
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/120091
Acceso en línea:https://hdl.handle.net/2445/120091
Access Level:acceso abierto
Palabra clave:Factors de creixement
Càncer d'ovari
Proliferació cel·lular
Growth factors
Ovarian cancer
Cell proliferation
Descripción
Sumario:There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development.